Bile acids improve the antimicrobial effect of rifaximin

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3618-3624

  Darkoh, Charles ^a   Lichtenberger, Lenard M ^a,b   Ajami, Nadim ^c   Dial, Elizabeth J ^a,b   Jiang, Zhi Dong ^d   DuPont, Herbert L ^a,b,c,d,e  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BETA GALACTOSIDASE; BILE ACID; RIFAXIMIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BACTERIAL STRAIN; BILE ACID BLOOD LEVEL; COLON; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; ENTEROTOXIGENIC ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SMALL INTESTINE;

ANTI-BACTERIAL AGENTS; BILE ACIDS AND SALTS; ENTEROTOXIGENIC ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS; RIFAMYCINS; SOLUBILITY;

EID: 77956100061     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00161-10     Document Type: Article

References (50)

1. Adachi, J. A., Z. D. Jiang, J. J. Mathewson, M. P. Verenkar, S. Thompson, F. Martinez-Sandoval, R. Steffen, C. D. Ericsson, and H. L. DuPont. 2001. Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin. Infect. Dis. 32:1706-1709.
2. Al-Abri, S. S., N. J. Beeching, and F. J. Nye. 2005. Traveler's diarrhoea. Lancet Infect. Dis. 5:349-360.
3. Begley, M., G. M. Cormac, and C. Hill. 2005. The interaction between bacteria and bile. FEMS Microbiol. Rev. 29:625-651.
4. Black, R. E. 1990. Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev. Infect. Dis. 12(Suppl. 1):S73-S79.
5. Black, R. E. 1993. Epidemiology of diarrhoeal disease: implications for control by vaccines. Vaccine 11:100-106. (Pubitemid 23031492)
6. Bortolini, O., A. Medici, and S. Poli. 1997. Biotransformations on steroid nucleus of bile acids. Steroids 62:564-577. (Pubitemid 27381668)
7. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
8. Brook, I. 1989. Aerobic and anaerobic microbiology of biliary tract disease. J. Clin. Microbiol. 27:2373-2375.
9. Carpenter, H. A. 1998. Bacterial and parasitic cholangastrointestinal tractis. Mayo Clin. Proc. 73:473-478.
10. Christiaens, H., R. J. Leer, P. H. Pouwels, and W. Verstraete. 1992. Cloning and expression of a conjugated bile acid hydrolase gene from Lactobacillus plantarum by using a direct plate assay. Appl. Environ. Microbiol. 58:3792-3798.
11. Cohen, D. E., M. Angelico, and M. C. Carey. 1990. Structural alterations in lecithin-cholesterol vesicles following interactions with monomeric and micellar bile salts: physical-chemical basis for subselection of biliary lecithin species and aggregative states of biliary lipids during bile formation. J. Lipid Res. 31:55-70.
12. Coleman, R., P. J. Lowe, and D. Billington. 1980. Membrane lipid composition and susceptibility to bile salt damage. Biochim. Biophys. Acta 599: 294-300.
13. De Smet, I., L. Van Hoorde, M. V. Woestyne, H. Christiaens, and W. Verstraete. 1995. Significance of bile salt hydrolytic activities of lactobacilli. J. Appl. Bacteriol. 79:292-301.
14. Doerner, K. C., F. Takamine, C. P. LaVoie, D. H. Mallonee, and P. B. Hylemon. 1997. Assessment of fecal bacteria with bile acid 7α- dehydroxylation activity for the presence of bai like genes. Appl. Environ. Microbiol. 63:1185-1188.
15. Dowling, R. H. 1973. The enterohepatic circulation of bile acids as they relate to lipid disorders. J. Clin. Pathol. 5:59-67.
16. DuPont, H. L., Z. D. Jiang, C. D. Ericsson, J. A. Adachi, J. J. Mathewson, and M. W. DuPont. 2001. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin. Infect. Dis. 33:1807-1815.
17. DuPont, H. L., and Z. D. Jiang. 2004. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin. Microbiol. Infect. 10:1009-1011.
18. DuPont, H. L., Z. D. Jiang, P. C. Okhuysen, C. D. Ericsson, F. J. de la Cabada, and S. Ke. 2005. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann. Intern. Med. 142:805-812.
19. Flores, C., I. Maguilnik, E. Hadlich, and L. Z. Goldani. 2003. Microbiology of choledochal bile in patients with choledocholithiasis admitted to a tertiary hospital. J. Gastroenterol. Hepatol. 18:333-336.
20. Gänzle, M. G., C. Hertel, J. M. B. van der Vossen, and W. P. Hammes. 1999. Effect of bacteriocin-producing lactobacilli on the survival of Escherichia coli and Listeria in a dynamic model of the stomach and the small intestine. Int. J. Food Microbiol. 48:21-35.
21. Gomi, H., Z. D. Jiang, J. A. Adachi, D. Ashley, B. Lowe, M. P. Verenkar, R. Steffen, and H. L. DuPont. 2001. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob. Agents Chemother. 45:212-216.
22. Gray, C. H., D. C. Nicholson, and R. V. Quincey. 1968. Fate of bile in the bowel, p. 2483-2505. In C. F. Code (ed.), Handbook of physiology, section 6, alimentary canal, vol. V. American Physiological Society, Washington, DC.
23. Grill, J. P., F. Schneider, J. Crociani, and J. Ballongue. 1995. Purification and characterization of conjugated bile salt hydrolase from Bifidobacterium longum BB536. Appl. Environ. Microbiol. 61:2577-2582.
24. Hardison, W. G. 1978. Hepatic taurine concentration and dietary taurine as regulators of bile acid conjugation with taurine. Gastroenterology 75:71-75. (Pubitemid 8378774)
25. Heuman, D. M., R. S. Bajaj, and Q. Lin. 1996. Adsorption of mixtures of bile salt taurine conjugates to lecithin-cholesterol membranes: implications for bile salt toxicity and cytoprotection. J. Lipid Res. 37:562-573. (Pubitemid 26134362)
26. Hofmann, A. F. 1999. Bile acids: the good, the bad, and the ugly. News Physiol. Sci. 14:24-29.
27. Hofmann, A. F. 1994. Bile acids, p. 677-718. In I. M. Arias, J. L. Boyer, N. Fausto, D. A. Jackoby, D. A. Schachter, and D. A. Shafritz (ed.), The liver: biology and pathobiology. Raven Press Ltd., New York, NY.
28. Infante, R. M., C. D. Ericsson, Z. D. Jiang, S. Ke, R. Steffen, and L. Riopel. 2004. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin. Gastroenterol. Hepatol. 2:135-138.
29. Jiang, Z. D., and H. L. DuPont. 2005. Rifaximin: in vitro and in vivo antibacterial activity - a review. Chemotherapy 51(Suppl. 1):67-72.
30. Jiang, Z. D., B. Lowe, M. P. Verenkar, D. Ashley, R. Steffen, and N. Tornieporth. 2002. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J. Infect. Dis. 185:497-502.
31. Lauritano, E. C., M. Gabrielli, A. Lupascu, A. Santoliquido, G. Nucera, and E. Scarpellini. 2005. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment. Pharmacol. Ther. 22:31-35.
32. Lundeen, S. G., and D. C. Savage. 1990. Characterization and purification of bile salt hydrolase from Lactobacillus sp. strain 100-100. J. Bacteriol. 172: 4171-4177.
33. Mallonee, D. H., and P. B. Hylemon. 1996. Sequencing and expression of a gene encoding a bile acid transporter from Eubacterium sp. strain VPI 12708. J. Bacteriol. 178:7053-7058.
34. Miller, J. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
35. Monte, M. J., J. J. G. Marin, A. Antelo, and J. Vazquez-Tato. 2009. Bile acids: chemistry, physiology, and pathophysiology. World J. Gastroenterol. 15:804-816.
36. Northfield, T. C., and I. McColl. 1973. Postprandial concentrations of free and conjugated bile acids down the length of the normal human small intestine. Gut 14:513-518.
37. Onyekaba, C. O., and H. O. Njoku. 1986. Bacteria and helminth isolated from bile and faeces of zebu cattle slaughtered for human consumption in the Niger Delta areas of Nigeria. Ann. Trop. Med. Parasitol. 80:421-424.
38. Owen, R. W. 1985. Biotransformation of bile acids by clostridia. J. Med. Microbiol. 20:233-238.
39. Poley, J. R., and A. F. Hofmann. 1976. Role of fat maldigestion in pathogenesis of steatorrhea in ileal resection. Fat digestion after two sequential test meals with and without cholestyramine. Gastroenterology 70:1125-1129.
40. Ruiza, J., L. Mensa, C. O'Callaghan, M. J. Pons, A. González, J. Vila, and J. Gascón. 2007. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. Diagn. Microbiol. Infect. Dis. 59:473-475.
41. Sierra, J. M., J. Ruiz, M. M. Navia, M. Vargas, J. Gascon, and J. Vila. 2001. In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea. Antimicrob. Agent Chemother. 45:643-644.
42. Sjovall, J. 1959. Dietary glycine and taurine on bile acid conjugation on man. Bile acids and steroids. Proc. Soc. Exp. Biol. Med. 100:676-678.
43. Steffen, R., F. Castelli, N. H. Dieter, L. Rombo, and J. N. Zuckerman. 2005. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J. Travel Med. 12:102-107.
44. Steffen, R., D. A. Sack, L. Riopel, Z. D. Jiang, M. Sturchler, and C. D. Ericsson. 2003. Therapy of travelers' diarrhea with rifaximin on various continents. Am. J. Gastroenterol. 98:1073-1078.
45. Taylor, D. N., A. L. Bourgeois, C. D. Ericsson, R. Steffen, Z. D. Jiang, and J. Halpern. 2006. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am. J. Trop. Med. Hyg. 74:1060-1066.
46. Taylor, D. N., R. McKenzie, A. Durbin, et al. 2006. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin. Infect. Dis. 42:1283-1288.
47. Taylor, D. N., R. McKenzie, A. Durbin, C. Carpenter, R. Haake, and A. L. Bourgeois. 2008. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob. Agents Chemother. 52:1179-1181.
48. Wells, J. E., and P. B. Hylemon. 2000. Identification and characterization of a bile acid 7α-dehydroxylation operon in Clostridium sp. strain TO-931, a highly active 7α-dehydroxylating strain isolated from human feces. Appl. Environ. Microbiol. 66:1107-1113.
49. Wenneras, C., and V. Erling. 2004. Prevalence of enterotoxigenic Escherichia coli-associated diarrhoea and carrier state in the developing world. J. Health Popul. Nutr. 22:370-382.
50. Zhang, X., and H. Bremer. 1995. Control of the Escherichia coli rrnB P1 promoter strength by ppGpp. J. Biol. Chem. 270:11181-11189.